Use the hyperlinks, where available to access additional clinical trial information.
TiNivo-2: A Phase 3, Randomized, Controlled, Multicenter, Open-label Study to Compare Tivozanib in Combination With Nivolumab to Tivozanib Monotherapy in Subjects With Renal Cell Carcinoma Who Have Progressed Following One or Two Lines of Therapy Where One Line Has an Immune Checkpoint Inhibitor
AVEO Pharmaceuticals, Inc.
Eligible participants will be randomly allocated to one of two experimental arms. In Experimental Arm A, participants will receive 0.89mg of tivozanib once daily (orally) for three weeks followed by week off, plus nivolumab every 4 weeks on Day 1 of each Cycle. In Experimental Arm B, participants will receive 1.34mg of tivozanib once daily (orally) for 3 weeks followed by 1 week off.